Shandong Lukang Pharmaceutical Co.,Ltd. (600789SS) DCF Valuation

Shandong Lukang Pharmaceutical Co., Ltd. (600789.SS) Évaluation DCF

CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHH
Shandong Lukang Pharmaceutical Co.,Ltd. (600789SS) DCF Valuation

Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets

Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur

Pré-Construits Pour Une Utilisation Rapide Et Efficace

Compatible MAC/PC, entièrement débloqué

Aucune Expertise N'Est Requise; Facile À Suivre

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplifier Shandong Lukang Pharmaceutical Co., Ltd. Évaluation avec cette calculatrice DCF personnalisable! Avec Real Shandong Lukang Pharmaceutical Co., Ltd. Les intrants de prévision financière et ajustable, vous pouvez tester des scénarios et découvrir Shandong Lukang Pharmaceutical Co., Ltd. juste valeur en minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue 4,205.1 4,890.7 5,621.4 6,093.0 6,233.1 6,886.5 7,608.4 8,406.1 9,287.3 10,260.9
Revenue Growth, % 0 16.3 14.94 8.39 2.3 10.48 10.48 10.48 10.48 10.48
EBITDA 570.7 486.2 596.3 741.9 910.9 838.9 926.8 1,024.0 1,131.4 1,250.0
EBITDA, % 13.57 9.94 10.61 12.18 14.61 12.18 12.18 12.18 12.18 12.18
Depreciation 245.5 309.7 350.0 382.6 401.6 428.6 473.5 523.2 578.0 638.6
Depreciation, % 5.84 6.33 6.23 6.28 6.44 6.22 6.22 6.22 6.22 6.22
EBIT 325.2 176.5 246.3 359.3 509.3 410.3 453.3 500.8 553.3 611.3
EBIT, % 7.73 3.61 4.38 5.9 8.17 5.96 5.96 5.96 5.96 5.96
Total Cash 648.8 555.2 690.1 799.7 773.8 889.7 982.9 1,086.0 1,199.8 1,325.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 858.3 824.4 1,232.2 1,346.1 1,791.8
Account Receivables, % 20.41 16.86 21.92 22.09 28.75
Inventories 869.1 1,205.6 1,480.7 1,406.0 1,484.2 1,632.7 1,803.9 1,993.0 2,201.9 2,432.7
Inventories, % 20.67 24.65 26.34 23.08 23.81 23.71 23.71 23.71 23.71 23.71
Accounts Payable 1,154.3 1,164.5 1,611.0 1,502.6 1,502.7 1,772.4 1,958.3 2,163.5 2,390.4 2,640.9
Accounts Payable, % 27.45 23.81 28.66 24.66 24.11 25.74 25.74 25.74 25.74 25.74
Capital Expenditure -703.1 -486.7 -428.4 -337.9 -279.2 -610.4 -674.4 -745.1 -823.2 -909.5
Capital Expenditure, % -16.72 -9.95 -7.62 -5.55 -4.48 -8.86 -8.86 -8.86 -8.86 -8.86
Tax Rate, % 9.05 9.05 9.05 9.05 9.05 9.05 9.05 9.05 9.05 9.05
EBITAT 282.7 138.4 226.4 324.0 463.2 359.8 397.5 439.2 485.2 536.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -748.0 -331.0 -88.3 221.2 61.7 575.6 52.4 57.9 64.0 70.7
WACC, % 5.79 5.72 5.83 5.82 5.82 5.79 5.79 5.79 5.79 5.79
PV UFCF
SUM PV UFCF 744.3
Long Term Growth Rate, % 3.00
Free cash flow (T + 1) 73
Terminal Value 2,606
Present Terminal Value 1,966
Enterprise Value 2,711
Net Debt 1,785
Equity Value 926
Diluted Shares Outstanding, MM 897
Equity Value Per Share 1.03

What You Will Receive

  • Genuine Shandong Lukang Data: Comprehensive financial insights – from revenue to EBIT – utilizing both actual and projected figures.
  • Complete Customization: Modify all essential parameters (highlighted cells) such as WACC, growth %, and tax rates.
  • Immediate Valuation Adjustments: Automatic recalculations to assess the effects of changes on Shandong Lukang's fair value.
  • Flexible Excel Template: Designed for quick modifications, scenario analysis, and extensive projections.
  • Efficient and Precise: Avoid constructing models from the ground up while ensuring accuracy and adaptability.

Core Highlights

  • Customizable Forecast Inputs: Adjust essential variables such as revenue growth, EBITDA percentage, and capital expenditures.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
  • Precision at a Professional Level: Utilizes Shandong Lukang Pharmaceutical's real financial data for accurate valuation results.
  • Simplified Scenario Analysis: Effortlessly examine various assumptions and analyze the resulting outcomes.
  • Efficient Valuation Tool: Removes the necessity of creating complex valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file for Shandong Lukang Pharmaceutical Co.,Ltd. (600789SS).
  2. Step 2: Review the pre-filled financial data and forecasts for Shandong Lukang.
  3. Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe how the DCF model updates in real-time as you adjust your assumptions.
  5. Step 5: Assess the outputs and leverage the results for your investment strategies.

Why Opt for Shandong Lukang Pharmaceutical Co., Ltd. Calculator?

  • Reliable Data: Accurate financials for Shandong Lukang ensure trustworthy valuation outcomes.
  • Tailorable: Modify essential parameters such as growth projections, WACC, and tax rates to align with your estimates.
  • Efficient: Pre-configured calculations save you time and effort in the analysis process.
  • Professional Tool: Crafted for use by investors, analysts, and consultants in the pharmaceutical sector.
  • Easy to Use: A user-friendly interface paired with clear instructions simplifies the process for everyone.

Who Can Benefit from This Product?

  • Pharmacy Students: Master pharmaceutical valuation techniques and apply them using real-world data.
  • Researchers: Integrate professional valuation models into your academic projects or studies.
  • Investors: Validate your investment strategies and assess valuation results for Shandong Lukang Pharmaceutical Co.,Ltd. (600789SS).
  • Market Analysts: Enhance your analysis process with a customizable and ready-to-use DCF model.
  • Healthcare Entrepreneurs: Understand how large pharmaceutical companies like Shandong Lukang are evaluated.

Contents of the Template

  • Preloaded 600789SS Data: Historical and forecasted financial information, encompassing revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Advanced worksheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Cells highlighted in yellow for modifying revenue growth, tax rates, and discount rates.
  • Financial Statements: Detailed annual and quarterly financial reports for in-depth analysis.
  • Key Ratios: Metrics for profitability, leverage, and efficiency to assess performance.
  • Dashboard and Charts: Visual representations of valuation results and underlying assumptions.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.